T1	PROC 44 80	Estudio de fase 3, abierto y cruzado
T2	PROC 98 116	autoadministración
T3	CHEM 121 136	rozanolixizumab
T4	LIVB 145 158	participantes
T5	DISO 177 180	gMG
T6	PROC 202 227	Estudio abierto y cruzado
T7	PROC 244 262	autoadministración
T8	CHEM 267 282	rozanolixizumab
T9	LIVB 291 304	participantes
T10	DISO 323 352	miastenia gravis generalizada
T11	DISO 378 394	miastenia gravis
#1	AnnotatorNotes T11	C0026896; Myasthenia Gravis; Disease or Syndrome
T12	DISO 402 428	enfermedad autoinmunitaria
#2	AnnotatorNotes T12	C0004364; Autoimmune Diseases; Disease or Syndrome
T13	DISO 439 464	debilidad en los músculos
T14	ANAT 519 526	nervios
#3	AnnotatorNotes T14	C0027740; Nerve; Body Part, Organ, or Organ Component | C1280541; Entire nerve; Body Part, Organ, or Organ Component
T15	ANAT 533 541	músculos
#4	AnnotatorNotes T15	C0026845; Muscle Tissue; Tissue | C1305763; Skeletal and/or smooth muscle structure; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T16	DISO 567 596	Miastenia gravis generalizada
T17	LIVB 629 642	participantes
T18	PROC 672 683	diagnóstico
#5	AnnotatorNotes T18	C0011900; Diagnosis; Diagnostic Procedure
T19	DISO 699 715	Miastenia gravis
#6	AnnotatorNotes T19	C0026896; Myasthenia Gravis; Disease or Syndrome
T21	LIVB 727 739	participante
T22	PROC 804 835	autoadministración domiciliaria
T23	LIVB 858 870	participante
T24	CHEM 890 905	rozanolixizumab
T25	PROC 918 929	Tratamiento
#7	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	PROC 975 988	Peso corporal
T27	LIVB 1003 1016	participantes
T28	LIVB 1040 1047	hombres
#8	AnnotatorNotes T28	C0025266; Male population group; Population Group | C0086418; Homo sapiens; Human
T29	LIVB 1050 1057	mujeres
#9	AnnotatorNotes T29	C0043210; Woman; Population Group | C0242665; wife; Family Group
T30	LIVB 1089 1101	participante
T31	DISO 1124 1141	hipersensibilidad
#10	AnnotatorNotes T31	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T32	CHEM 1187 1198	medicamento
#11	AnnotatorNotes T32	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T33	CHEM 1219 1257	medicamentos anti-receptor Fc neonatal
T34	CHEM 1259 1263	FcRn
T35	LIVB 1268 1280	Participante
T36	DISO 1301 1326	infección de tuberculosis
T37	DISO 1328 1330	TB
#12	AnnotatorNotes T37	C0005586; Bipolar Disorder; Mental or Behavioral Dysfunction | C0040586; Tracheobronchitis; Disease or Syndrome | C0041296; Tuberculosis; Disease or Syndrome
T38	Spec_cue 1351 1360	riesgo de
T39	DISO 1374 1389	infección de TB
T40	Speculated 1374 1389	infección de TB
T41	DISO 1396 1429	infección de tuberculosis latente
T42	Speculated 1396 1429	infección de tuberculosis latente
T43	DISO 1431 1435	LTBI
T44	Speculated 1431 1435	LTBI
T45	DISO 1444 1487	infección por micobacterias no tuberculosas
T46	Speculated 1444 1487	infección por micobacterias no tuberculosas
T47	Date 1488 1494	actual
T48	DISO 1507 1512	NTMBI
T49	Speculated 1507 1512	NTMBI
T50	LIVB 1519 1531	participante
T51	DISO 1554 1563	infección
#13	AnnotatorNotes T51	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T52	DISO 1612 1621	infección
#14	AnnotatorNotes T52	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T53	PROC 1644 1659	hospitalización
#15	AnnotatorNotes T53	C0019993; Hospitalization; Health Care Activity
T54	PROC 1671 1682	tratamiento
#16	AnnotatorNotes T54	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T55	CHEM 1687 1699	antibióticos
#17	AnnotatorNotes T55	C0003232; Antibiotics; Antibiotic
T56	Route 1704 1719	vía intravenosa
T57	Duration 1731 1744	las 6 semanas
T58	PROC 1761 1767	visita
T59	LIVB 1781 1793	participante
T60	CHEM 1852 1867	rozanolixizumab
T61	PROC 1915 1921	retiro
T62	PROC 1924 1960	interrupción obligatoria del fármaco
T63	LIVB 1979 1991	participante
T64	CHEM 2020 2031	vacuna viva
T65	Duration 2042 2055	las 4 semanas
T66	PROC 2077 2088	tratamiento
#18	AnnotatorNotes T66	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T67	CHEM 2096 2130	vacuna de Bacillus Calmette Guérin
T68	CHEM 2132 2135	BCG
#19	AnnotatorNotes T68	C0004886; BCG Vaccine; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance | C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T69	Duration 2147 2152	1 año
T70	PROC 2174 2185	tratamiento
#20	AnnotatorNotes T70	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T71	CHEM 2223 2234	vacuna viva
T72	Duration 2276 2289	las 8 semanas
T74	CHEM 2323 2338	rozanolixizumab
T75	LIVB 2341 2353	Participante
T76	DISO 2370 2379	debilidad
#21	AnnotatorNotes T76	C0424594; Frailty; Finding | C3714552; Weakness; Sign or Symptom
T78	DISO 2467 2483	miastenia gravis
#22	AnnotatorNotes T78	C0026896; Myasthenia Gravis; Disease or Syndrome
T79	ANAT 2500 2537	músculos orofaríngeos o respiratorios
T80	DISO 2555 2572	crisis miasténica
T81	DISO 2579 2585	crisis
#23	AnnotatorNotes T81	C0036572; Seizures; Sign or Symptom | C0231224; Crisis; Finding
T82	DISO 717 720	gMG
T20	PROC 2415 2454	escala de actividades de la vida diaria
T77	PROC 2456 2462	MG-ADL
T83	DISO 1868 1870	MG
